Program
balcinrenone
Also written as “AZD9977”, “Balcinrenone/dapagliflozin” and “balcinrenone/ dapagliflozin”.
Its studies are mostly in Heart Failure · Renal Insufficiency · Renal Insufficiency, Chronic · Fasting · Cardiovascular Diseases, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 151 open or running | phase 3since May 29, 2026 | Jun 18, 2015 | Jul 1, 2030phase 3 · NCT07624305 |
- Named in AstraZeneca’s own pipeline as
balcinrenone/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: fortrea, parexel and quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jun 18, 2015.
- Aug 24, 2015Phase 1 study in PharmacodynamicsNCT02532998 · 40 enrolled · United Kingdom
- Sep 24, 2015Phase 1 study in PharmacokineticsNCT02560363 · United Kingdom
- Jan 25, 2018Phase 1 study in Heart FailureNCT03435276 · 27 enrolled · United Kingdom
- Feb 15, 2018Phase 1 study in Heart FailureNCT03450759 · 13 enrolled · United Kingdom
- Sep 21, 2018Phase 1 study in Heart FailureNCT03682497 · 68 enrolled · Bulgaria, Czechia, Poland and more
- Dec 12, 2018Phase 1 study in Heart FailureNCT03801967 · 28 enrolled · United Kingdom
- Feb 14, 2019Phase 1 study in Heart FailureNCT03843060 · 14 enrolled · United States
- Jun 19, 2020Phase 1 study in Renal InsufficiencyNCT04469907 · 18 enrolled · United States
- Dec 17, 2020Phase 1 study in Cardiovascular DiseasesNCT04686591 · 8 enrolled · United Kingdom
- Apr 16, 2024Phase 1 study in Hepatic ImpairmentNCT06388616 · 30 enrolled · United States
- Sep 25, 2024Phase 1 study in Healthy VolunteerNCT06651021 · 10 enrolled · China
- May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT06979388 · 14 enrolled · United Kingdom
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicPhase 3 reachedNCT07624305 · 2,800 planned · United States, Argentina, Austria and more
- Jul 13, 2026Phase 1 study in Renal InsufficiencyNCT07754331 · 10 enrolled · United States
Ahead
- Jul 1, 2030Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07624305
TargetBeta
“Mineralocorticoid receptor modulator”ChEMBL 37, by rule
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 25 |
| drospirenonerule | estetra | phase 4 | 20 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Spironolactonerule | cmp-development-llc | phase 4 | 8 |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07754331Renal Insufficiency · United States | 1 | Completed | Oct 6, 2026 | 10 |
| NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more | 3 | Recruiting | Jul 1, 2030 | 2,800 |
| NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom | 1 | Completed | Jul 12, 2025 | 14 |
| NCT06651021Healthy Volunteer · China | 1 | Completed | Oct 28, 2024 | 10 |
| NCT06388616Hepatic Impairment · United States | 1 | Completed | Sep 5, 2024 | 30 |
| NCT04686591Cardiovascular Diseases · United Kingdom | 1 | Completed | Feb 4, 2021 | 8 |
| NCT04469907Renal Insufficiency · United States | 1 | Completed | Oct 28, 2021 | 18 |
| NCT03843060Heart Failure · United States | 1 | Completed | Apr 1, 2019 | 14 |
| NCT03801967Heart Failure · United Kingdom | 1 | Completed | May 2, 2019 | 28 |
| NCT03682497Heart Failure · Bulgaria, Czechia, Poland and more | 1 | Terminated | Mar 31, 2020 | 68 |
| NCT03450759Heart Failure · United Kingdom | 1 | Completed | Jun 6, 2018 | 13 |
| NCT03435276Heart Failure · United Kingdom | 1 | Completed | Jun 13, 2018 | 27 |
| NCT02560363Pharmacokinetics · United Kingdom | 1 | Withdrawn | Jan 2016 | 0 |
| NCT02532998Pharmacodynamics · United Kingdom | 1 | Completed | Dec 2015 | 40 |
| NCT02484729Safety · United Kingdom | 1 | Completed | Nov 2015 | 196 |
How it is read
Names in the registry
- “AZD9977”, 5 entries
- “Balcinrenone/dapagliflozin”, 2 entries
- “balcinrenone/ dapagliflozin”, 1 entry
- “balcinrenone/dapagliflozin”, 1 entry
- “Balcinrenone”, 1 entry
Codes read as this program: AZD9977.
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Renal Insufficiency, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Fasting, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.